Rifampin-based tuberculosis treatment can cause subtherapeutic concentrations of protease inhibitors and virologic failure in children receiving antiretroviral therapy. Among 217 children on antiretroviral therapy, tuberculosis cotreatment (in 78) was associated with virologic failure. Ritonavir-based single protease inhibitor antiretroviral therapy regimen predicted virologic failure (adjusted odds ratio 3.7, 95% confidence interval 1.5–8.9, P = 0.004) on multivariate analysis.
From the *Department of Paediatrics and Child Health, Desmond Tutu TB Centre, Stellenbosch University; †Department of Paediatrics, University of Cape Town; ‡Department of Paediatrics and Child Health, Tygerberg Children’s Hospital, Stellenbosch University, Cape Town, South Africa; and §Department of Paediatrics and Child Health, Sydney Institute for Emerging Infections and Biosecurity, The Children’s Hospital at Westmead, University of Sydney, Sydney, Australia.
Accepted for publication October17, 2012.
E.W. received support from the Faculty of Medicine and Health Sciences at Stellenbosch University (employing institution) for travel related to this work in 2011 (3rd Pediatric HIV Workshop in Rome, Italy). The authors have no other funding or conflicts of interest to disclose.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s website (www.pidj.com).
Address for correspondence: Elisabetta Walters, FCPaed, MMed, Desmond Tutu TB Centre, Faculty of Medicine and Health Sciences, P. O. Box 19063, Tygerberg 7505, Cape Town, South Africa. E-mail: firstname.lastname@example.org.